Hella Sand looked at rigid v deformable reg for lung #reirradiation. Both performed well, with good inter-centre consistency, but less variation for DIR, especially for cumulative max dose. Results have driven recommendations in the CURE Lung reRT trial #radonc #medphys #ESTRO25

Isak Wahlsted led a national study of dose accumulation for #reirradiation: 8 diverse cases evaluated in all Danish RT centres

Image reg was consistent & high quality; but differences in a/b & tissue recovery gave substantial intercentre variation in cumulative dose #medphys #radonc #ESTRO25

Inter-centre variation in image registration for #reirradiation from DK: Two great studies from collaborators presented at #ESTRO25
Conclusions: Image registration-based dose accum for reRT is feasible. For lung, DIR is better than RIR. Radiobio factors largest source of variation #radonc #medphys

Fantastic talk by Corinne Faivre-Finn on women in radiation oncology and the changes which needs to be made. Congratulations with the award.

Impressive OS for reRT in lung cancer presented by Marianne Knap from Aarhus University Hospital

I am so excited to get all the work on reirradiation started and looking forward for the collaboration with people in the group and all others being interested

I am so excited to get all the work on reirradiation started and looking forward for the collaboration with people in the group and all others being interested

Sarah Eckholdt presenting the robustness results of the European phase III PROTECT trial showing very good compliance with the trial requirements on dose delivery

Sarah Eckholdt presenting the robustness results of the European phase III PROTECT trial showing very good compliance with the trial requirements on dose delivery

For even more #reirradiation highlights and discussion, join the dedicated conference WhatsApp group!
#ESTRO25 #medphys #radonc

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non–Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial PURPOSERadiation dose escalation for locally advanced non–small cell lung cancer (LA-NSCLC) has been challenged by toxicity concerns. The Scandinavian phase III multicenter dose-escalation trial NARLA...

Can you dose escalate locally advanced NSCLC to 88+ Gy without excess toxicity?
Yes! If you use heterogeneous dose escalation & careful QA.

6-month toxicity data from the Scandinavian phase III dose escalation NARLAL2 trial now online in JCO:
ascopubs.org/doi/abs/10.1...
#radonc

Absolutely no difference in toxicity profiles between 66Gy and dose escalation; even when considering lower grade events or time profiles
(Major caveat: we’re only reporting toxicity up to 6 months at this point - but we’ve not seen any signals in the late toxicity so far either)

The first Italian PROTECT patient has been treated with protons at the Trento Proton Therapy Centre. Read more on why Trento participates in the PROTECT study, protonterapia.provincia.tn.it/eng/News-and...

Fuld day workshop on reRT with participation from all Danish RT clinics. The aim is to set up a Danisk registration protokol for reRT

Overview of the PROTECT RTQA program

The PROTECT RTQA paper has been published: medicaljournalssweden.se/actaoncologi...